Associate Professor of Law
Associate Professor Jordan Paradise researches and publishes on the legal, ethical, and societal implications of emerging science and technologies such as genetics and nanotechnology. She joined the Seton Hall University School of Law as an Associate Professor in 2009. She teaches Food & Drug Law, Administrative Law and an Advanced Writing seminar.
Professor Paradise is actively involved in collaborative, interdisciplinary projects that examine the intersection of law, science and technology. She has served as an Investigator on several other private and federal grants addressing topics of law and science, including grants from the Greenwall Foundation, the National Science Foundation and the National Institutes of Health. Her publications have appeared in both peer-reviewed and legal publications, including Science; Nature Reviews Genetics; Risk Analysis; Journal of Law, Medicine & Ethics; Food & Drug Law Journal; Yale Journal of Health Policy, Law & Ethics; Minnesota Journal of Law, Science & Technology; Temple Journal of Science, Technology & Environmental Law; and the International Journal of Intellectual Property Management.
Professor Paradise previously served as the Associate Director of Research & Education for the Joint Degree Program in Law, Health & the Life Sciences and the Consortium on Law and Values in Health, Environment & the Life Sciences at the University of Minnesota Law School from 2005-2009. She was also an Adjunct Associate Professor of Law, a Research Associate in the Center for Bioethics, and the Faculty Editor-in-Chief of the Minnesota Journal of Law, Science & Technology during her time at the University of Minnesota. From 2003-2005, Professor Paradise served as a Research Fellow at the Institute for Science, Law and Technology housed at Chicago-Kent College of Law and the Illinois Institute of Technology in Chicago, Illinois. She received her B.S. from the University of Michigan in Ann Arbor and her J.D. from Chicago-Kent College of Law with a certificate in Intellectual Property Law. She is a member of the Illinois Bar.
LAW REVIEW ARTICLES
No Sisyphean Task: The FDA Can Utilize the Tobacco Control Act to Regulate Electronic Cigarettes, 13 Yale J. Health Pol'y, L. & Ethics 1-32 (2013)
Reassessing 'Safety' for Nanotechnology Combination Products: What Do 'Biosimilars' Add to Regulatory Challenges for the FDA?, 56 St. Louis U. L.J. 1-55 (2012)
Claiming Nanotechnology: Improving USPTO Efforts at Classification of Emerging Nano-Enabled Pharmaceutical Technologies, 10(3) Northwestern Journal of Technology and Intellectual Property 169-207 (2012)
Synthetic Biology: Does Re-Writing Nature Require Re-Writing Regulation?, 117 Penn. State L. Rev. 53-88 (2012) (with Ethan Fitzpatrick)
The Devil is in the Details: Health Care Reform, Biosimilars, and Implementation Challenges for the Food and Drug Administration, 51 JURIMETRICS 279-292 ((2011))
Follow-On Biologics: Implementation Challenges and Opportunities, 41 Seton Hall L. Rev. 501-509 (2011)
Exploring Emerging Nanobiotechnology Drugs and Medical Devices, 63(2) Food and Drug L.J. 407-420 (2008) (with Gail M. Diliberto, Alison W. Tisdale, & Efrosini Kokkoli)
Developing Oversight Frameworks for Nanobiotechnology, 9(1) Minnesota J. L. Science & Tech. 187-203 (Winter 2008) (with Susan M. Wolf, Gurumurthy Ramachandran, Efrosini Kokkoli, Ralph Hall, & Jennifer Kuzma)
Tales from the Crypt: Scientific, Ethical, and Legal Considerations for Biohistorical Analysis of Deceased Historical Figures, 26 Temple J. Of Science, Tech. & Environ. Law 223-299 (Fall 2007) (with Lori Andrews)
Lessons from the European Union: The Need for a Post-Grant Mechanism for Third Party Challenge to U.S. Patents, 7(1) Minnesota J.L. Science & Tech. 315-326 (2005)
Gene Patents: The Need for Bioethics Scrutiny and Legal Change, 5 Yale J. Health Pol'y, L. & Ethics 403-412 (2005) (with Lori Andrews)
European Opposition to Exclusive Control Over Predictive Breast Cancer Testing and the Inherent Implications for United States Patent Law and Public Policy: A Case Study of the Myriad Genetics’ BRCA Patent Controversy, 59(1) Food and Drug L.J. 133-154 (2004)
OTHER JOURNAL ARTICLES
Recommendations for Oversight of Nanobiotechnology: Dynamic Oversight for Complex and Convergent Technologies, Journal of Nanoparticle Research DOI: 10.1007/s11051-011-0233-2 (February 2011) (Gurumurthy Ramachandran, Susan M. Wolf, Jennifer Kuzma, Ralph Hall, Efrosini Kokkoli and Leili Fatehi)
The Challenge of Developing Oversight Approaches to Nanobiotechnology, 37(4) J.L. Med. & Ethics 543-545 (2009) (with Susan M. Wolf, Jennifer Kuzma, Gurumurthy Ramachandran, and Efrosini Kokkoli)
Evaluating Oversight of Human Drugs and Medical Devices: A Case Study of the FDA and Implications for Nanobiotechnology, 37(4) J.L. Med. & Ethics 598-624 (2009) (with Alison W. Tisdale, Ralph Hall, & Efrosini Kokkoli)
Developing U.S. Oversight Strategies for Nanobiotechnology: Learning from Past Oversight Experiences, 37(4) J. L. Med. & Ethics 688-705 (2009) (with Susan M. Wolf, Jennifer Kuzma, Aliya Kuzhabekova, Alison W. Tisdale, Gurumurthy Ramachandran, and Efrosini Kokkoli)
Patient Advocacy Group Collaboration in Genetic Research and The Scope of Joint Inventorship under U.S. Patent Law, 3(2) Int'l J. OF INTELLECTUAL PROPERTY MANAGEMENT 97-109 (2009)
An Integrated Approach to Oversight Assessment for Emerging Technologies, 28(5) RISK ANALYSIS 1197-1220 (2008) (with Jennifer Kuzma, Gurumurthy Ramachandran, Jee-Ae Kim, Adam Kokotovich, & Susan M. Wolf)
The Law of Incidental Findings in Human Subjects Research, 36(2) J.L.Med. & Ethics 361-383 (2008) (with Susan M. Wolf & Charlisse Caga-anan)
Managing Incidental Findings in Human Subjects Research: Analysis and Recommendations, 36(2) J. L. Med. & Ethics 219-248 (2008)
When Patents Threaten Science, 314 Science 1395-96 (2006) (with Lori Andrews, Timothy Holbrook, & Danielle Bochneak)
Decoding the Research Exemption, 7(2) Nature Reviews Genetics 148-154 (2006) (with Christopher Janson)
Problems in Patenting Human Genes, 308 Science 1869 (2005) (with Lori Andrews & Timothy Holbrook)
Call for Biohistory Guidelines, 2 PLOS MEDICINE e192 (2005)
Patents on Human Genes: An Analysis of Scope and Claims, 307 Science 1566-1567 (2005) (with Lori Andrews & Timothy Holbrook)
Constructing Ethical Guidelines for Biohistory, 304 Science 214-215 (2004) (with Lori Andrews, Nancy Buenger, Jennifer Bridge, Laurie Rosenow, David Stoney, R.E. Gaensslen, Theodore Karamanski, Russell Lewis, Amy Inlander, & David Gonen)
Human Genome Research and Return of Research Results, Encyclopedia of Bioethics, 4th Ed. (forthcoming 2014) (Bruce Jennings, Lisa Eckenwiler, Gregory Kaebnick, Barbara Koenig, Sheldon Krimsky, Stephen R. Latham, Mark R. Mercurio, eds.)
The Trans Fat Smackdown, HEALTH REFORM WATCH.COM (Nov. 11, 2013)
Funding, and Ethics, for the BRAIN Initiative, HEALTH REFORM WATCH.COM (Oct. 1, 2013)
Nanobiotechnology and the FDA, Food and Drug Law Institute's UPDATE MAGAZINE (March/April 2010)
Banning Gene Patents Can Bring Benefits, 1(39) BIOWORLD TODAY (September 20, 2007) (with Lori Andrews)
National Conference on Research Cloning, PERSPECTIVES: THE MAGAZINE FOR THE UNIVERSITY OF MINNESOTA LAW SCHOOL (Spring 2007)
BOOKS AND BOOK CHAPTERS
Introduction to Biologics, in Chapter 3 in THE FUNDAMENTALS OF LIFE SCIENCES LAW: DRUGS, DEVICES, AND BIOTECH, American Health Lawyers Association, 2nd Ed. (forthcoming 2014)
Genetic Sequence Patents: Historical Justification and Current Impacts, in Jean-Paul Gaudillière, Daniel J. Kevles, Hand-Jörg Rheinberger, eds., MAX PLANCK INSTITUTE FOR THE HISTORY OF SCIENCE, LIVING PROPERTIES: MAKING KNOWLEDGE AND CONTROLLING OWNERSHIP IN THE HISTORY OF BIOLOGY 137- 163 (2009) (with Lori Andrews)
Gene Patents and Bioethics, in TOWARDS A DECLARATION ON UNIVERSAL NORMS ON BIOETHICS EXTRAORDINARY SESSION OF THE INTERNATIONAL BIOETHICS COMMITTEE, in (2004) (with Lori Andrews)
Prabuddha Ganguli & Siddharth Jabade, Nanotechnology Intellectual Property Rights: Research, Design, and Commercialization, 34(4) World Patent Information 319-320 (2012)
The BRAIN Initiative: Law, Policy, Ethics, Lehigh University, Bethlehem, PA (Nov. 21, 2013)
The BRAIN Initiative: Law, Policy, Ethics, New Jersey Institute of Technology, Newark, NJ (Nov. 6, 2013)
Different Risk, Different Name?: The Debate over Nonproprietary Naming of Biosimilar Biologics, Arizona State University Sandra Day O’Connor School of Law, 1st Annual Governance of Emerging Technologies: Law, Policy, and Ethics, Phoenix, AZ (May 21, 2013)
Working in the Food and Drug Law Space: Challenges and Opportunities, Food and Drug Law Institute Annual Conference, Washington, D.C. (Apr. 24, 2013)
Gene Patents at the Supreme Court, New Jersey Institute of Technology, Newark, NJ (Apr. 17, 2013)
FDA I & II: Pharmaceutical Regulatory and Compliance Fundamentals, Sidley Austin Life Sciences College, New York, NY (Feb. 26, 2013)
Implementation of the Biologics Price Competition and Innovation Act, Gibbons PC and Institute for Law, Science & Technology, Newark, NJ (Feb. 19, 2013)
A Sisyphean Task?: How the FDA Can Effectively Utilize the Tobacco Control Act to Regulate Electronic Cigarettes, AALS Annual Meeting, New Voices in Administrative Law, New Orleans, LA (January 5, 2013)
Assessing FDA Regulation of New Drugs, Animal Drugs, and Cosmetics As Applied to Microbes Modified Using Synthetic Biology, J. Craig Venter Institute, Rockville, MD (January 31, 2012)
Synthetic Biology: Does Re-Writing Nature Require Re-Writing Regulations?, 35th Annual ASLME Health Law Professors Conference, Tempe, AZ (June 9, 2012)
Developments in the Center for Biologics Evaluations and Research, 55th Annual Food & Drug Law Institute Conference, Washington, DC (April 25, 2012) (Moderator)
An Overview of the Food and Drug Administration, Seton Hall MSJ Open House (October 20, 2012) (Newark, NJ)
Sottera v. FDA: Electronic Cigarettes and the Tobacco Control Act of 2009, Food & Drug Law Institute, 54th Annual Conference , Washington, DC (April 6, 2011)
Synthetic Biology Meets the Law, AALS Annual Meeting, Biolaw Section, San Francisco, CA (January 5, 2011)
The Devil is in the Details: Health Care Reform, Biosimilars, and Implementation Challenges for the Food and Drug Administration, 3rd Annual Pharmaceutical Reimbursement & Market Access Conference, Philadelphia, PA (October 28, 2011)
The Biologics Price Competition and Innovation Act: FDA and Biosimilars , Seton Hall University School of Law, Follow-On Biologics: Implementation Challenges and Opportunities Roundtable, Newark, NJ (October 29, 2010)
Developing Oversight for Nanobiotechnology: Human Drugs and Medical Devices, University of Massachusetts,, Nanotechnology & Society: Emerging Organizations, Oversight, and Public Policy Systems Conference, Amherst, MA (September 24, 2010)
Current Legal Status of Follow-On Biologics, American Society of Law, Medicine and Ethics 33rd Annual Health Law Professors Conference, Austin, TX (June 4, 2010)
Consensus Recommendations on Nanobiotechnology Oversight, Governing Nanobiotechnology: Reinventing Oversight in the 21st Century Conference, U. of Minnesota, Minneapolis, MN (April 15, 2010)
The FDA, Nanodrugs, and Implications for Healthcare, American Society of Law, Medicine & Ethics 32nd Annual Health Law Professors Conference, Cleveland, OH (June 5, 2009)
National Science Foundation, Grant 0608791, NIRT: Evaluating Oversight Models for Active Nanostructures and Nanosystems: Learning from Past Technologies in a Societal Context, September 2006-August 2010. Role: Co-Pincipal Investigator.
The Greenwall Foundation, Emerging Problems in Neurogenomics: Ethical, Legal & Policy Issues at the Intersection of Genomics & Neuroscience, November 1, 2007-May 31, 2008. Role: Co-Investigator.
National Institutes of Health, Grant 5R01HG003178, Managing Incidental Findings in Human Subjects Research, September 2005-July 2007 (Susan Wolf, Principal Investigator). Role: Working Group Member.
Robert Wood Johnson Foundation , Grant 047723, Impact of Gene Patents on the Delivery of Health Care Services, September 2003-August 2005 (Lori Andrews, Principal Investigator). Role: legal researcher and policy analyst.
Department of Energy, Grant DE-FG02-02ER63460, Complex Genetic Disorders and Intellectual Property Rights, September 2002-August 2005 (Lori Andrews & Timothy Holbrook, Principal Investigators). Role: Legal researcher and policy analyst.
National Science Foundation, Grant 0134850, Ethical, Legal, and Technical Issues of Biohistorical Research, June 2002-May 2004 (Lori Andrews, Principal Investigator). Role: legal researcher and policy analyst.